Dialysis world news


National Registry Study Evaluating Utility of SPRIX® (ketorolac ... - MarketWatch (press release)

SHIRLEY, N.Y., June 25, 2012 /PRNewswire via COMTEX/ -- Regency Therapeutics, a division of Luitpold Pharmaceuticals, Inc., announced today that a national registry has been launched by a group of academic emergency medicine specialists led by Charles Pollack, MA, MD, FAAEM, FACEP, FAHA, Professor and Chairman, Department of Emergency Medicine, Pennsylvania Hospital, University of Pennsylvania Health System. The purpose of the registry is to evaluate patient experience with SPRIX® (ketorolac tromethamine) Nasal Spray, a non-narcotic pain medication, in the management of pain associated with certain medical problems that cause patients to seek medical care in the emergency department. Outcomes will be compared to those of patients who are prescribed oral narcotics for pain relief. The study, called AMPED (Acute Management of Pain from the Emergency Department), will compare the overall impact - efficacy, safety, economics and patient satisfaction - of these different approaches to pain management from a patient's perspective. SPRIX® Nasal Spray, the first and only intranasal non-steroidal anti-inflammatory drug (NSAID), was approved by the U.S. Food and Drug Administration (FDA) in May 2010 for the short-term management (up to 5 days) of moderate to moderately severe pain that requires analgesia at the opioid level.

"Moderate to moderately severe pain is one of the most common reasons patients seek care in emergency departments, but emergency department clinicians often do not provide adequate treatment of pain because of ingrained prescribing habits and concerns about the appropriate use of narcotic analgesics," said Dr. Pollack. "One of the goals of our study is to understand the overall impact of acute pain and its different treatments on patients after they leave the emergency department, including patient satisfaction, quality of life, and back-to-work/normal activities outcomes."

More than 12 million people in the United States report using opioid or narcotic pain relievers non-medically[i] and, according to the U.S. Centers for Disease Control and Prevention (CDC), these drugs are involved in more overdose deaths than cocaine and heroin combined.[ii] In 2009, the misuse and abuse of prescription painkillers was responsible for more than 397,000 emergency department visits, or 129.4 visits per 100,000 people, nearly twice as many as heroin (~213,000 visits, or 69 visits per 100,000 people).[iii] The active ingredient in SPRIX® (ketorolac tromethamine) Nasal Spray is not a narcotic (does not bind to opioid receptors) and is non-addictive. In clinical trials, patients showed no withdrawal symptoms upon cessation of ketorolac treatment.[iv]

"We are very interested in comparing the response of emergency room patients to SPRIX® vs. narcotics during the management of acute moderate to moderately severe pain. By providing funds to a group of academically oriented emergency medicine physicians to design and carry out this trial, we felt we could obtain high quality information of interest to both of us," said David Bregman, MD, PhD, Medical Director, Luitpold Pharmaceuticals.

The AMPED study will be led by Dr. Pollack and Knox H. Todd, MD, MPH, FACEP, Professor and Chair of the Department of Emergency Medicine, University of Texas MD Anderson Cancer Center. Joining Drs. Pollack and Todd on the registry's steering committee are emergency medicine physicians Deborah Diercks (UC Davis Medical Center, Sacramento, CA), Sharon Mace (Cleveland Clinic Foundation, Cleveland, OH), and Stephen Thomas (University of Oklahoma, Tulsa), and pharmacist John Fanikos (Brigham and Women's Hospital, Boston, MA). AMPED will be conducted at fifteen sites around the nation. Approximately 1,000 patients are expected to be enrolled over an eighteen-month period. Patients will receive SPRIX® and/or a narcotic for the management of acute pain at the time of discharge. Patients will be followed for five days to evaluate a variety of outcomes, including pain relief, adverse effects, activity/work patterns, healthcare resource utilization, and quality of life measures. The AMPED study will be funded by Regency Therapeutics, and conducted by Radnor Registry Research (St Davids, PA) at the 15 participating emergency departments. The study opens to enrollment next month.

"We designed this registry to help us understand better what the options are for treating pain after discharge from the emergency department and how the way we treat pain impacts the total patient experience as they re-enter their lives," said Dr. Todd. "The emergency department, unfortunately, can be a gateway for the misuse and abuse of narcotics. As emergency care providers, we need to balance the real need to treat acute pain, but also manage our responsibility to our patients and the community. Hopefully, this study will help provide us a framework for evaluating alternatives to narcotics for treatment of moderate to moderately severe pain."

Please see Important Safety Information following, including Boxed Warning. For additional information about SPRIX® (ketorolac tromethamine) Nasal Spray please visit www.SPRIX.com .

About Luitpold Pharmaceuticals, Inc.Luitpold Pharmaceuticals, Inc., a Daiichi Sankyo Group Company headquartered in Shirley, NY, manufactures over 80 pharmaceutical products including Venofer® (iron sucrose injection, USP), the # 1 selling IV iron therapy in the U.S., which are distributed through its human health subsidiary, American Regent, Inc. Luitpold Pharmaceuticals, also markets dental bone regeneration products and veterinary pharmaceuticals through its Osteohealth and Animal Health divisions respectively. For more information on Luitpold or any of its divisions, please visit: www.luitpold.com .

About Regency TherapeuticsRegency Therapeutics, a division of Luitpold Pharmaceuticals, Inc., markets innovative pharmaceutical products that offer meaningful alternatives to patients and those that care for them. Currently focused on the treatment of acute pain, Regency seeks to provide fiscally and socially responsible solutions to challenging problems facing customers and the health care system. For more information, please visit: www.regencytherapeutics.com .

About Daiichi Sankyo The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information, please visit www.daiichisankyo.com .

IMPORTANT SAFETY INFORMATION

WARNING: LIMITATIONS OF USE, GASTROINTESTINAL, BLEEDING, CARDIOVASCULAR, and RENAL RISK

Limitations of UseSPRIX® (ketorolac tromethamine) Nasal Spray, a nonsteroidal anti-inflammatory drug (NSAID), is indicated for short-term (up to 5 days in adults) management of moderate to moderately severe pain that requires analgesia at the opioid level. Do not exceed a total combined duration of use of SPRIX® and other ketorolac formulations (IM/IV or oral) of 5 days.

SPRIX® is not indicated for use in pediatric patients and it is not indicated for minor or chronic painful conditions.

Gastrointestinal RiskKetorolac tromethamine, including SPRIX®, can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, SPRIX® is contraindicated in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events.

Bleeding RiskKetorolac tromethamine inhibits platelet function and is, therefore, contraindicated in patients with suspected or confirmed cerebrovascular bleeding, patients with hemorrhagic diathesis, incomplete hemostasis and those at high risk of bleeding.

Cardiovascular RiskNSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk.

SPRIX® (ketorolac tromethamine) Nasal Spray is contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.

Renal RiskSPRIX® is contraindicated in patients with advanced renal impairment and in patients at risk for renal failure due to volume depletion.

SPRIX® is contraindicated in patients with known hypersensitivity or history of asthma, urticaria, or other allergic-type reactions to aspirin, ketorolac, other NSAIDs or EDTA. However, anaphylactoid reactions may occur in patients with or without a history of allergic reactions to aspirin or NSAIDs. SPRIX® is contraindicated in patients as a prophylactic analgesic prior to major surgery; or in labor, delivery, or nursing mothers because of the potential adverse effects of prostaglandin-inhibiting drugs on neonates.

SPRIX® should not be used concomitantly with IM/IV or oral ketorolac, aspirin, or other NSAIDs, or with probenecid or pentoxifylline. When ketorolac is administered with aspirin, its protein binding is reduced, although the clearance of free ketorolac is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of SPRIX® and aspirin is not generally recommended because of the potential of increased adverse effects.

Do not use SPRIX® in patients for whom hemostasis is critical.

Clinical studies, as well as postmarketing observations, have shown that ketorolac can reduce the natriuretic effect of furosemide and thiazides in some patients.

Concomitant use of ACE inhibitors and/or angiotensin II receptor antagonists may increase the risk of renal impairment, particularly in volume-depleted patients. NSAIDs may diminish the antihypertensive effect of ACE inhibitors and/or angiotensin II receptor antagonists. Consider this interaction in patients taking SPRIX® concomitantly with ACE inhibitors and/or angiotensin II receptor antagonists.

Ketorolac can cause serious GI adverse events including bleeding, ulceration, and perforation. Elderly patients are at increased risk for serious GI events.

Use SPRIX® with caution in patients with impaired hepatic function or a history of liver disease.

The pharmacologic activity of SPRIX® in reducing inflammation and fever may diminish the utility of these diagnostic signs in detecting infections.

Avoid contact of SPRIX® (ketorolac tromethamine) Nasal Spray with the eyes. If eye contact occurs, wash out the eye with water or saline, and consult a physician if irritation persists for more than an hour.

Ketorolac can cause renal injury. SPRIX® Nasal Spray should be used with caution in patients with advanced renal disease or patients at risk for renal failure due to volume depletion and should be used with caution in patients taking diuretics or ACE inhibitors. Long-term administration of NSAIDs has resulted in renal papillary necrosis and other renal injury such as interstitial nephritis and nephrotic syndrome.

NSAIDs can cause serious dermatologic adverse reactions such as exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which can be fatal. These serious events may occur without warning. SPRIX® should be discontinued immediately in patients with skin reactions.

During pregnancy, use of SPRIX® beyond 30 weeks' gestation can cause premature closure of the ductus arteriosus, resulting in fetal harm (Pregnancy Category D). Prior to 30 weeks' gestation, SPRIX® should be used during pregnancy only if potential benefit justifies the potential risk to the fetus (Pregnancy Category C).

NSAIDs can lead to onset of new hypertension or worsening of preexisting hypertension, either of which may contribute to the increased incidence of cardiovascular events. Patients taking thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs. Fluid retention, edema, retention of NaCl, oliguria, and elevations of serum urea nitrogen and creatinine have been reported in clinical trials with ketorolac. Only use SPRIX® (ketorolac tromethamine) Nasal Spray very cautiously in patients with cardiac decompensation or similar conditions.

The most common adverse reactions (incidence greater than or equal to 2%) in patients treated with SPRIX® and occurring at a rate at least twice that of placebo are nasal discomfort, rhinalgia, increased lacrimation, throat irritation, oliguria, rash, bradycardia, decreased urine output, increased ALT and/or AST, hypertension, and rhinitis.

Treat patients for the shortest duration possible, and do not exceed 5 days of therapy with SPRIX®.

Please see complete Prescribing Information, including Boxed Warning at www.SPRIX.com .

SP0073, Iss. 6/2012

[i] U.S. Centers for Disease Control and Prevention (CDC). "Prescription Painkiller Overdoses in the U.S." Accessed 5/15/12. Available at: http://www.cdc.gov/Features/VitalSigns/PainkillerOverdoses/

[ii] CDC. Vital Signs: Overdoses of Prescription Opioid Pain Relievers --- United States, 1999-2008. Morbidity and Mortality Weekly Report (MMWR). November 4, 2011; 60(43):1487-1492. Accessed 5/15/12. Available at: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6043a4.htm

[iii] U.S. Substance Abuse & Mental Health Services Administration (SAMHSA). Highlights of the 2009 Drug Abuse Warning Network (DAWN) Findings on Drug-Related Emergency Department Visits. The DAWN Report. December 28, 2010. Accessed 5/15/12. Available at: http://www.oas.samhsa.gov/2k10/DAWN034/EDHighlightsHTML.pdf

[iv] SPRIX® [package insert]. Shirley, NY: American Regent, Inc; 2011.

SOURCE Regency Therapeutics

Copyright (C) 2012 PR Newswire. All rights reserved

...

 
CVD Tied to Reduced Kidney Function in Renal Transplant Patients - Renal and Urology News

Lower kidney function is independently associated with an increased risk of cardiovascular disease (CVD) and death in stable kidney transplant recipients, according to investigators.

At an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m2, each 5 mL/min/1.73 m2 increment in eGFR is associated with a 15% decreased risk of both CVD and death, researchers reported online in the American Journal of Transplantation. The investigators, led by Daniel E. Weiner, MD, of Tufts Medical Center in Boston, observed no association between eGFR and outcomes at eGFR levels above 45.

“The presence of an association between low eGFR and cardiovascular disease in transplant recipients suggests that comorbid conditions associated with low GFR itself rather than concurrent comorbidities that result in both low eGFR as well as systemic cardiovascular disease may be impacting cardiovascular risk,” the investigators wrote.

Reduced eGFR is independently associated with CVD events and mortality in the general population, the researchers noted. “Finding a similar relationship in kidney transplant recipients as in the general population suggests a possible direct effect of reduced GFR, since the transplanted kidney is likely to not have had a long exposure to traditional and nontraditional CVD risk factors,” the authors stated.

Dr. Weiner and his colleagues conducted a post-hoc analysis of data from 4,016 participants in the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) trial—which included patients who received a kidney transplant at least six months before enrollment. Over a median of 3.8 years, 527 CVD events occurred in the 3,676 subjects who had complete data.

They pointed out that their study has multiple strengths, including a large cohort, extensive ascertainment of CVD risk factors, systematic prospective ascertainment of CVD events, and the measurement of serum creatinine by a single laboratory. The study also has some weaknesses, including a lack of data on albuminuria and only a single assessment of serum creatinine for eGFR determination.

...

 
African-Americans less likely to receive kidney donation, study shows - CNN
African-Americans less likely to receive kidney donation, study shows - CNN Carmichael Griffin has been on dialysis and awaiting a kidney transplant for nearly 12 years. (CNN) -- Carmichael Griffin didn't think anything of it when his face began to swell. He assumed he had just gained a couple of pounds. But when the swelling progressed to severe vomiting and frequent urination, he knew something was wrong. It turned out that both of his kidneys were failing. He was suffering from hypertension, a common ailment among African-American patients. "My blood pressure had scarred my kidneys so much they were surprised I didn't have a stroke then," said Griffin, 32. "I was a walking time bomb." That was nearly 12 years ago. The Washington-based music producer and actor has been on dialysis and awaiting a kidney transplant since then. A study published this month by the American Journal of Kidney Diseases shows that African-American patients awaiting a new organ are less likely to get one than non-black patients. At the 275 transplant centers in the United States, African-Americans had at least a 35% lower chance of receiving a live kidney donation, said Dr. Erin Hall of the Department of Surgery at the Johns Hopkins University School of Medicine. At some centers, African-Americans had a 76% lower chance of getting an organ. The study surveyed 247,707 adults registered for first-time kidney transplants from 1995 to 2007. About 92,000 people in the United States are on a waiting list for a kidney transplant. More than one-third are African-Americans, according to the National Kidney Foundation. In 2011, 5,771 living donor transplants were performed, 813 on African-American patients. "African-Americans had lower odds of obtaining living donor kidney transplantation at every transplant center in the country," Hall said. Living donor transplants -- donations of an organ or part of an organ from a live person -- are the best option. A kidney from a living donor usually starts to function immediately. In some cases, a kidney from a deceased donor may require a patient to remain on dialysis until it begins to function. The racial disparity may be attributed to education levels, economic factors or medical characteristics such as blood type, Hall said. Also, some centers may be more focused on deceased kidney transplants, she said. "There's also a higher prevalence of obesity and diabetes [among African-Americans] that would preclude you to become a donor," Hall said. Griffin believes there's a lack of support and knowledge about kidney donation among African-Americans. He has asked family and friends for help, but to no avail. "I am exhausted," he said. "I have a couple of white friends who received transplants and a few black friends whose families donated it to them. Makes me wonder what I'm doing wrong." He says more education is needed, that potential donors need to know that it's not a life sentence for them. "Of course living donor kidney transplantation involves not only the recipient of the kidney, but also the donor," Hall said. "It could be the social networks of African-American populations." Hall advises frustrated African-American patients that it is never too late to take control of their medical care, and to continue to ask. She suggests patients educate themselves more on the process of living organ donation so that they become more comfortable speaking with potential donors. "If we continue to fight for them, and they continue to fight for themselves, we can reach a good solution," Hall said. Griffin has stopped asking family and friends for an organ, but he continues to produce music and act. His hope is that he can one day do those things away from a dialysis machine. We recommend

...

 
To Swani Gandu - AllAfrica.com

Today, I will be paying tribute to a friend who has touched me beyond measure. I have known Swani Gandu since the 1980s when both of us lived and worked in Kaduna. He worked at RIMS Merchant Bank and I, with Pfizer Products Plc. I can't remember exactly how we became very close but we gravitated towards each other. I visited him regularly in his office and, occasionally, at his home. We heartily discussed the politics of the day then, including the politics of the military government. In time, I also became close to his lovely wife, Comfort. Though we were exactly the same age, Swani got married long before most of us. He was much wiser.

Swani had always had a keen sense of humour. We laughed and laughed together as he would always find a good reason to laugh, and his laughter was infectious. He was also quite mischievous. He gave some of his friends different kinds of funny names. I will not mention the name he contrived for me.

As we grew up, our paths naturally drifted as we found new vocations. In time, he left RIMS and got absorbed with running Joy International School - a family business owned by his father - on the outskirts of Kaduna. For my part, I started spending more time in Abuja before finally moving in with my family.

The next time I heard from Swani was in 2003 when he called and wanted to join The Buhari Organisation (TBO). I was TBO's spokesman and deputy director-general then. I invited him to Abuja but, along the line, he got appointed assistant registrar of the Kaduna State College of Education, Gidan Waya, near Kafanchan. His wife was also employed as a lecturer in the college. Both of them are still in the employ of the institution.

And now to the crux of this column today: Swani didn't know he had been afflicted with diabetes that had even reached the advanced stages. One thing led to the other and he was forced to have a series of tests. After the tests, two of his toes had to be amputated at once. That was four years ago. And, since then, he has been walking around with excruciating pains with his feet permanently wrapped in bandage because sores and wounds in severely diabetic patients don't heal. My suspicion - even though I have not confirmed this anywhere - is that Swani must have been a little careless with his diet, as a diabetic patient. His current situation is worse than that of most diabetics I know - and I have very close friends that are diabetics and you'll hardly know, if they don't disclose their condition.

In a double whammy, about four years ago, a doctor in Kaduna carelessly and mistakenly injected him with antibiotics that are contraindicated in diabetics. Every doctor should know the relationship between Gentamicin, diabetes and the kidneys. The doctor administered Gentamicin to Swani and, before anyone knew what was happening, my friend had lost both his kidneys.

So that was how Swani, a decent and pleasant man, has been living in the last four years with severe diabetes and with no kidneys. Even though he is only 50, he now looks much older and more infirm than his father, who must be closer to 80 than he looks. But Swani is much happier than many of us. He is a very positive person and you will see that in him whenever he is not contending with the severe pains he is going through.

I didn't know how bad Swani's condition was until two days ago. A few months ago, he called to inform me that he was putting together an NGO, Kidney Care and Support Initiative, and he wanted me and a few others like Senator Esther Nenadi Usman and Dauda Iliya to be on the board of trustees. I accepted immediately, not because I knew the import of what he was about doing but simply because Swani was an old and trusted friend. He also requested to use the boardroom of LEADERSHIP for the NGO's meetings. I have not been able to attend any of the meetings because I was always out of the country whenever meetings were called. But he insisted that I drop all my programmes to attend the annual general meeting of the foundation and the board of trustees' meeting two days ago. I did, and that was when I saw Swani physically, the first time in 10 years.

Swani's positive attitude indicts all of us. Even though I had not set eyes on him for up to 10 years, we spoke often and nothing in his voice betrayed what he was going through. He was always his most cheerful self. Because he has lost his kidneys, he is not allowed to drink water because the water would get into the lungs and choke him, and, according to his wife, he has had close shaves several times. He is only allowed to lick ice. He also probably spends nearly half a million naira monthly to handle his ailments but that has not put him down either.

Attending the AGM on Saturday was an invaluable education for me. Two brilliant nephrologists, Dr Gimba Mark of the Jos University Teaching Hospital and Dr Lekan Olatise, the medical director of Zenith Medical and Kidney Centre, Abuja, presented excellent but heartrending papers on the challenges faced by kidney patients especially in an unjust country like Nigeria. That was when I knew that Swani probably spends nearly half a million naira every month, to manage his condition.

Swani said it was during his treatment that he met a little girl who died simply because she could not afford the money for dialysis. It costs an average of N25,000 for a session of dialysis and, since most patients must do it two times a week, it is not difficult to see why most of those who have this ailment in Nigeria die before their time.

And this is only because of the very irresponsible governments that this country has had. Most countries, including the very poor ones, are not like that. In spite of the poverty and the never-ending war in the Sudan, their leaders offer free dialysis services to their people. It is also free in countries like Egypt and South Africa. In Nigeria, only a couple of states have been that thoughtful and people-friendly. Katsina State offers free dialysis services to its indigenes. Bauchi State charges only N5,000 for everyone. That is very good but, even with that, most of those with the ailment will not be able to afford N10,000 weekly to remain alive. And in the whole of Nigeria with 774 local government areas, there are only about 50 places dialysis is done. So, every day, hundreds and thousands of afflicted Nigerians queue around these centres. Many will die before it is their turn, even with their money. Nigeria has a federal government and leaders who do not care two hoots about the people they rule over. That is the only thing that would explain why President Jonathan would jet out to Brazil when parts of his country were on fire. If the Jonathan government can corruptly share N2.6 trillion "subsidy money" among 140 contractors, many of whom did not supply a drop of fuel, then, you will understand how wicked those who govern Nigeria are. If Sudan, a much poorer country, can offer free dialysis to its people, then, you know Nigeria doesn't have leaders.

As government was doing nothing, Swani decided to set up the NGO. He didn't embark on this for himself. He obviously is able to afford it and he clearly doesn't want people to pity him. He was moved to set it up after witnessing the death of a little girl who was unable to afford the treatment. It is quite moving that, even though Swani is a victim himself, he has decided to help other victims who are less privileged.

When Swani's father, Barau Gandu, Tafidan Jaba, spoke during the meeting two days ago, he was full of praises for the son he was painfully proud of and ended by saying - in a reference to the NGO - that he was glad something good had come out of Swani's painful condition. Swani has used his ailment to bless others less privileged than he is. He then prayed for Swani. That was the only time I noticed my friend in tears.

During the programme, I sat with another friend, Thomas Etuh, who was the chairman of the occasion. In the course of our side talk, Thomas placed a few calls to suppliers to find out the cost of a new dialysis machine. That was when we found out that the best and most sophisticated ones cost less than N5 million a piece. Thomas immediately pledged to construct a dialysis centre for the Kidney Care and Support Initiative. Another person who touched me in the gathering was Dare Awonugba who works with the AIT to find support for sick and helpless people in need. After Dare spoke, Thomas pledged N500,000 to a little sick girl he emotionally talked about. Dare burst into tears.

Swani's example is that, whatever you are going through in life, you can always live a full life. As I said earlier, even though he is almost incapacitated by these ailments, he is obviously happier than many people I know. Immediately he saw me at the meeting, he called me by the funny name he alone had been calling me since the last 20-plus years we have known ourselves, bursting into a hearty laughter in the process. Swani is obviously still his very mischievous self.

Another person that has wowed me in all of this is Comfort, Swani's wife. Her equanimity, stability and strength of character is humbling. She is a wonderful wife and a wonderful mother. She is obviously a gift not only to Swani and their children, but to all of us. She is the type every wife should be.

My earnest prayer for Swani is that he should continue to live life to the fullest and for a very long time for that matter. And thank you, Swani, for teaching me life's lessons.

Jonathan's Cold-blooded Presidency

The world was shocked that President Goodluck Jonathan could jet out of the country when major parts of his country were literally on fire. But, apparently, he and his advisers saw nothing wrong with that. His minister of information, Labaran Maku, stretched common sense to the limits as usual, when he said the president can rule from anywhere - the same kind of nonsense we heard from Michael Aondoakaa, President Umaru Yar'Adua's attorney-general, when the late president was nowhere to be found. In certain circumstances, the most intelligent thing for advisers to do is keep quiet. It's obvious that it is only when the people's votes count that leaders take them seriously.

But Jonathan has always been like that. Since the conflagration started in Yobe and Borno states, the president has not been thoughtful enough to visit those states to assure the people. And, on a recent visit to South Korea, he said there was trouble only in a small part of Nigeria, in response to questions from people worried about the security situations of the country. You would think he is not also the president of that "small part". Compare this to presidents Bush and Obama who had visited US troops in Iraq and Afghanistan several times to show solidarity. We must ensure that the people's vote start counting in this country.

...

 
NGO Raises Funds to Fight Renal Disease - AllAfrica.com

The Kidney Care and Support Initiative, a Non-Governmental Organisation (NGO) has raised the total sum of N5, 035.000 and pledges of two dialysis centers in support of people living with Kidney diseases.

The fund raising took place yesterday during the first annual general meeting/ the fund raising of the organisation in Abuja where the Chairman, Board of Trustees of the organisation, Mr. Swani B. Gandu appealed for a more compassionate approach to issues related to renal disease.

Associating themselves with the goals of the organisation, the Chairman LEADERSHIP Newspapers Group, Mr. Sam Nda- Isaiah and the Chairman of Tak Continental Group, Mr. Thomas Etuh both made personal donations of One million naira each to the organisation.

In his remarks, Mr. Gandu said that most Nigerians have lost their lives to kidney diseases not because there is no treatment but for the financial burden that has been placed on them in the course of getting the treatment.

"The idea to set up this organisation came to me four years ago when I lost my kidney and have to be placed on dialysis for survival. The treatment has taken me to various cities and it was during these trips that I saw the sufferings of my fellow Nigerians.

"Though dialysis has been improved upon in Nigeria, the prices still differ in various dialysis centers and there are people who cannot afford them. Some of these people need this dialysis three or four times in a week. Most of these people are dying, not because there is no treatment, but because of the financial burden which has been placed on them. "

Stating the reason for the high rate of Kidney diseases in Nigeria, Head, Department of Nephrology, Jos University Teaching Hospital, Dr. Emmanuel Agaba, represented by Dr. Gimba Mark revealed that hypertension, as well as drug abuse are the commonest causes of kidney diseases in Nigeria.

"The risk factors for kidney diseases are hypertensions, diabetes, and chronic glomeluron nephritis are usually the three commonest and diabetes is the commonest cause of kidney diseases worldwide, but hypertension and chronic are the most common in Nigeria. Also are lots of things that we do like use of drugs without prescriptions such as the pain killers, herbal medicines. "

...

 
<< Start < Prev 291 292 293 294 295 296 297 298 299 300 Next > End >>

Page 294 of 2630
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.